Callan JMB Announces Arrival of Rapid Dose Therapeutics’ QuickStrip™, Resulting in $15 Million in Projected Revenue Over the Next 18 months

(NASDAQ:CJMB) Callan JMB, Inc. announced the receipt of a complete QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics Corp. for installation at its Texas facility. The delivery of this manufacturing system marks a significant milestone in Callan JMB’s strategy to expand its pharmaceutical services platform through domestic manufacturing, packaging, fulfillment, and distribution. The new equipment enables Callan JMB to enter the U.S. market for innovative oral thin-film drug delivery products. The collaboration leverages RDT’s proprietary QuickStrip™ technology and Callan JMB’s infrastructure, regulatory expertise, healthcare logistics network, and pharmaceutical distribution capabilities. Once installed, the production line will support U.S.-based manufacturing of fast-dissolving oral thin-film products for pharmaceutical, nutraceutical, and government healthcare applications. Callan JMB currently believes the oral thin-film manufacturing platform will generate up to $15 million in revenue during the first 18 months of operation, following successful qualification of the equipment. Wayne Williams, Chief Executive Officer of Callan JMB, stated that this shipment is an important milestone in building a comprehensive U.S.-based pharmaceutical manufacturing and healthcare logistics platform. Williams emphasized the company’s ongoing implementation of capabilities to strengthen healthcare supply chain resiliency, support domestic manufacturing, and create long-term value for customers and shareholders. He also noted that oral thin-film delivery technology is among the most promising segments of pharmaceutical innovation. Williams further stated that neither the completion of this project nor the recently announced IV Bag manufacturing facility require Callan JMB to raise any additional capital. QuickStrip™ is Rapid Dose Therapeutics’ proprietary oral thin-film drug delivery platform, utilizing rapidly dissolving oral strips designed for efficient and convenient delivery of active ingredients without water or traditional dosage forms. The platform has potential applications across pharmaceuticals, nutraceuticals, wellness products, emergency preparedness programs, and other healthcare markets. Callan JMB provides fulfillment, warehousing, cold-chain logistics, monitoring, regulatory compliance, specialty packaging, pharmaceutical support services, and emergency preparedness solutions to healthcare organizations, government agencies, and commercial customers. The company is building a platform spanning healthcare and pharmaceutical logistics, domestic pharmaceutical manufacturing, critical electrical infrastructure, specialty industrial manufacturing, preparedness services, and energy development through strategic partnerships, acquisitions, and organic growth initiatives.